Skip to content

Research on the popularization and application of external treatment of traditional Chinese medicine in the intervention of community acquired pneumonia in children

Research on the popularization and application of external treatment of traditional Chinese medicine in the intervention of community acquired pneumonia in children

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000656
Enrollment
Unknown
Registered
2024-11-05
Start date
2024-09-27
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pneumonia

Interventions

Fuxiong powder group:Basic treatment of Western medicine + external use of Fuxiong powder
Xiaoer Qingre Xuanfei plaster group:Basic treatment of Western medicine + pediatric Qingre Xuanfei plaster for external use

Sponsors

The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the criteria for Western medicine diagnosis and traditional Chinese medicine differentiation in CAP; (2) Age range from 1 to 14 years old; (3) Agree to cooperate with medication and undergo evaluation according to the requirements of the experimental protocol; (4) The informed consent of the legal guardian of the subject must be obtained and a voluntary informed consent form must be signed; When participants are able to make decisions to participate in clinical trials their consent must also be obtained.

Exclusion criteria

Exclusion criteria: (1) Individuals who are allergic to the experimental drug or its formulation ingredients or have an allergic constitution; (2) Complications of combined pneumonia (empyema pneumothorax pulmonary bullae etc.) severe pneumonia; (3) Merge severe primary diseases such as heart liver kidney digestive and hematopoietic systems as well as psychiatric patients; (4) Individuals who have participated in clinical trials within the past three months.

Design outcomes

Primary

MeasureTime frame
Cough Visual Analog Scale (VAS) score;Time window for the efficacy of pediatric pneumonia;The total response rate of the disease;

Secondary

MeasureTime frame
Individual symptoms and pulmonary signs;Medication compliance;Comparison of blood routine and C-reactive protein levels;Patient Efficacy Satisfaction Questionnaire (ESQ);Improvement in quality of life rating( EQ-5D );TCM syndrome effect;Conversion rate;

Countries

China

Contacts

Public ContactWANG Xuefeng

The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

lnzywxf@163.com13840208807

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026